Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404306 | 1.00 | MAPT (0.42) | MAPTABCC4TBXAS1SLC1A1CA2 | |
| SCHEMBL20139943 | 0.94 | MAPT (0.45) | MAPTABCC4TBXAS1SLC1A1CA2 | |
| SCHEMBL3944731 | 0.94 | MAPT (0.45) | MAPTABCC4TBXAS1SLC1A1CA2 | |
| SCHEMBL3779386 | 0.89 | ABCC4 (0.46) | MAPTABCC4TBXAS1CA2MAPK1 | |
| SCHEMBL7003560 | 0.86 | ABCC4 (0.41) | MAPTABCC4TBXAS1CA2MAPK1 | |
| SCHEMBL5975672 | 0.85 | MAPT (0.48) | MAPTABCC4CA2MAPK1GRIK1 | |
| SCHEMBL5494036 | 0.85 | ABCC4 (0.43) | MAPTABCC4TBXAS1CA2MAPK1 | |
| SCHEMBL2135519 | 0.83 | GRIK1 (0.50) | MAPTABCC4TBXAS1CA2MAPK1 | |
| SCHEMBL4016679 | 0.83 | MAPT (0.50) | MAPTABCC4CA2MAPK1GRIK1 | |
| SCHEMBL7975761 | 0.82 | FOLH1 (0.52) | MAPTABCC4TBXAS1CA2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538526-B1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| CN-110167934-B | Cyclobutane-and azetidine-containing monocyclic and spiro compounds as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3538526-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2018089355-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20090203631-A1 | PEPTIDE DEFORMYLASE INHIBITORS AS NOVEL ANTIBIOTICS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-13 | — | — | US | disclosed |
| US-7538085-B2 | Macrocyclic peptide antibiotics; drug resistant, drug sensitive bacterial infections | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-05-26 | — | — | US | disclosed |
| US-20070259812-A1 | Peptide deformylase inhibitors as novel antibiotics | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2007-11-08 | — | — | US | disclosed |
| US-7208595-B2 | Peptide deformylase inhibitors as novel antibiotics | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050026821-A1 | Peptide deformylase inhibitors as novel antibiotics | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | MAPT 1177/4885ABCC4 1951/4885TBXAS1 514/4885 |
| US-20090203631-A1 | PEPTIDE DEFORMYLASE INHIBITORS AS NOVEL ANTIBIOTICS | PDF, PADI3, PADI6 | MAPT 4179/4885ABCC4 2985/4885TBXAS1 2194/4885 |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | MAPT 1315/4885ABCC4 1754/4885TBXAS1 402/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | MAPT 864/4885ABCC4 2044/4885TBXAS1 425/4885 |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | MAPT 738/4885ABCC4 2039/4885TBXAS1 598/4885 |
| US-20070259812-A1 | Peptide deformylase inhibitors as novel antibiotics | PDF, PADI3, PADI6 | MAPT 4179/4885ABCC4 2985/4885TBXAS1 2194/4885 |
| US-20050026821-A1 | Peptide deformylase inhibitors as novel antibiotics | PDF, PADI3, PADI6 | MAPT 4179/4885ABCC4 2985/4885TBXAS1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.